Cifuentes: Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine [HCQ]

Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine

Cifuentes et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2020.10.012

Cifuentes et al., Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine, Medicina Clínica (English Edition), doi:10.1016/j.medcle.2020.10.012

Jan 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 3,817 chronic HCQ patients showing 4.4% COVID-19 positive rate, 1.3% severe. There is no comparison with a control group. Authors note that there was a 3.6% incidence among 2,032,863 patients in one of the regions (Castilla La Mancha), however they provide no information on this group - it is expected that the mostly systemic autoimmune disease patients in the treatment group are older on average. Additonally, other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 [Ferri].

1. Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7, COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series, https://link.springer.com/article/10.1007/s10067-020-05334-7.

Important missing comments or errors? Let us know.

Cifuentes et al., 23 Jan 2021, peer-reviewed, 18 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: Med Clin (Barc). 2021;156(4):166–171 www.elsevier.es/medicinaclinica Original article Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine夽 Francisco Tejada Cifuentes a,∗ , Ángeles Lloret Callejo a , María José Tirado Peláez a , Olga Rubio Pulido b , Marta Ruiz-Morote Aragón c , Rocío Fernández Urrusuno d , María Isabel Muñoz Carreras e , María Isabel Méndez Esteban f , Victoria Maestre Sánchez g , Antonio García Bonilla h , José Manuel Paredero Dominguez i , Virginia Arroyo Pineda j , Esther Marco Tejón k , Gregorio Romero Candel l , Ana Isabel Fernández Marchante m , José Marco del Rio n , Teresa Ortiz Martín o , Piedad López Sánchez p a Gerencia de Atención Integrada de Albacete, Albacete, Spain Gerencia de Atención Primaria de Toledo, Toledo, Spain c Gerencia de Atención Integrada de Puertollano, Puertollan, Spain d Distrito Sanitario Aljarafe, Sevilla, Spain e Gerencia de Atención Integrada, Alcázar de San Juan, Alcázar de San Juan, Spain f Área de Gestión Sanitaria Campo de Gibraltar, Cádiz, Spain g Distrito Sanitario Condado Campiña, Huelva, Spain h Área de Gestión Sanitaria Jerez, Costa Noroeste y Sierra de Cádiz, Jerez, Spain i Gerencia de Atención Integrada, de Guadalajara, Guadalajara, Spain j Gerencia de Atención Integrada Talavera de la Reina, Talavera de la Reina, Spain k Gerencia de Atención Integrada de Cuenca, Cuenca, Spain l Gerencia de Atención Integrada de Hellín, Hellín, Spain m Gerencia de Atención Integrada de Villarrobledo, Villarrobledo, Spain n Gerencia de Atención Integrada de Almansa, Almansa, Spain o Gerencia de Atención Integrada de Valdepeñas, Valdepeñas, Spain p Gerencia de Atención Integrada de Tomelloso, Tomelloso, Spain b a r t i c l e i n f o Article history: Received 22 August 2020 Accepted 16 October 2020 Available online 23 January 2021 Keywords: COVID-19 Coronavirus Incidence Hydroxychloroquine Treatment a b s t r a c t Objective: To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine. Patients and methods: Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the ﬁrst recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded. Results: 169 (4,45%) patients had Covid-19 infection, of which 12 (7.1 %) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P < .05). Maculopathy appears in 5.3% of patients and is signiﬁcantly related to the dose of hydroxychloroquine consumed (P < .05). Conclusion: There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19. © 2020 Elsevier España, S.L.U. All rights reserved. 夽 Please cite this article as: Tejada Cifuentes F, Lloret Callejo Á, Tirado Peláez MJ, Rubio Pulido O, Ruiz-Morote Aragón M, Fernández Urrusuno R, et al. Incidencia de la COVID-19 en pacientes en tratamiento crónico con hidroxicloroquina. Med Clin (Barc). 2021;156:166–171. ∗ Corresponding author. E-mail address: ftejada@sescam.jccm.es (F. Tejada Cifuentes). 2387-0206/© 2020 Elsevier España, S.L.U. All rights reserved. F. Tejada Cifuentes et al. / Med Clin (Barc)...

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit